There are currently 487 active clinical trials seeking participants for Breast Cancer research studies. The states with the highest number of trials for Autism participants are California, Ohio, Illinois and Michigan.
Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients
NCT04751435
Recruiting
Genetic testing is a type of test that detects changes to the genes-the DNA instructions that are passed on from the mother and father. The results of a genetic test can confirm whether the participant has a genetic disorder, which is a disease caused in whole or in part by changes to the genes. Genetic testing can also help determine a person's chance of getting or passing on a genetic disorder. Genetic tests use a sample of blood, hair, skin, or other tissue, and they can look at one gene or m... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Kings County Hopsital Center, Brooklyn, New York +1 locations
Conditions: Educational Materials for Genetic Testing, Breast Cancer, Ovarian Cancer, Prostate Cancer, Pancreatic Cancer
Register for Updates
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
NCT05646862
Recruiting
This is a Phase III, multicenter, randomized, open-label, global study designed to evaluate the efficacy and safety of inavolisib plus fulvestrant compared with alpelisib plus fulvestrant in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) -negative, PIK3CA-mutated, locally advanced (LA) or metastatic breast cancer (mBC), who progressed during or after cyclin dependent kinase 4/6i (CDK4/6i)-based therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: Marin Cancer Care Inc, Greenbrae, California +160 locations
Conditions: Breast Cancer
Register for Updates
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
NCT04569747
Recruiting
This research study is studying a combination of HER2-directed therapies (trastuzumab and pertuzumab) and hormonal therapy as a treatment after surgery for hormone receptor positive breast cancer. The study drugs involved in this study are: A combination of trastuzumab and pertuzumab given as an injection under the skin (PHESGO) Hormonal (endocrine) Treatment
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: Stamford Hospital, Stamford, Connecticut +25 locations
Conditions: HER2-positive Breast Cancer, Invasive Carcinoma of the Breast, Breast Cancer, Node Negative Breast Cancer, Micrometastasis Breast Cancer, Hormone Receptor Positive Breast Cancer
Register for Updates
ATEMPT 2.0: Adjuvant T-DM1 vs TH
NCT04893109
Recruiting
This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of the study drugs involved are: Trastuzumab-emtansine (T-DM1, Kadcyla) Trastuzumab SC (Herceptin Hylecta) Paclitaxel
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California +46 locations
Conditions: Breast Cancer, HER2-positive Breast Cancer
Register for Updates
THRIVE Study: Positive Affect Training for Endocrine Therapy Medication Adherence
NCT06388304
Recruiting
The purpose of this study is to pilot and refine an online behavioral intervention based on Positive Affect Training (PAT) that aims to increase positive emotional attitudes and decrease negative emotional attitudes toward endocrine therapy (ET, i.e., anti-hormonal medication) and to increase positive affect and decrease negative affect more generally, among post-treatment breast cancer survivors who are prescribed ET to prevent recurrence of breast cancer.
Gender:
Female
Ages:
21 years and above
Trial Updated:
04/24/2024
Locations: University of Colorado Boulder, Boulder, Colorado
Conditions: Breast Cancer, DCIS
Register for Updates
Early Detection of Breast Cancer in Women With Suspicious Mammograms
NCT03147430
Recruiting
This is a non-treatment study. It will not involve the use of any investigational drug or device. Potential participants will be enrolled through direct contact with collaborating clinical sites when the patient's annual 3D mammogram report yields a BIRADS rating of 4-5. The clinical Investigators or a member of their staff will conduct consent discussion once a suspicious mammogram report is identified or if a patient is referred for imaging of a suspicious area in the breast. After consenting... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: Dorothy G Hoefer Comprehensive Breast Center, Newport News, Virginia +1 locations
Conditions: Breast Cancer
Register for Updates
A Study of Blood Pressure Control During Cancer Treatment
NCT06023576
Recruiting
The purpose of this study to find out whether an intensive approach to treating high blood pressure during breast cancer treatment is safe and more effective than standard blood pressure treatment at lowering blood pressure levels and the risk of cardiotoxicity in patients with cancer. Other studies have shown lowering blood pressure improves the health of patients. However, these studies have not included people with cancer. The PROTECT trial is testing a treatment strategy regarding intensive... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +6 locations
Conditions: Breast Cancer, Cardiotoxicity
Register for Updates
A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
NCT05852691
Recruiting
The purpose of this study is to assess the efficacy and safety of a novel immunotherapy candidate, tobemstomig, in combination with nab-paclitaxel, for patients with previously untreated, locally advanced, unresectable or metastatic (Stage IV) programmed death-ligand 1 (PD-L1)-positive triple-negative breast cancer (TNBC).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Cancer Blood and Specialty Clinic, Los Alamitos, California +70 locations
Conditions: Breast Cancer
Register for Updates
HIIT Following Breast Cancer Chemotherapy
NCT05913713
Recruiting
Chemotherapy is an effective breast cancer treatment, which helped to increase the 5-year survival rate to approximately 95%. However, breast cancer survivors have a higher risk of cardiovascular disease (CVD) due to chemotherapy than adults without cancer. Cardiovascular rehabilitation can be an effective strategy to decrease the incidence of CVD and its risk factors in this population. The proposed study may help to examine the effect and durability of a novel high-intensity interval training... Read More
Gender:
Female
Ages:
Between 18 years and 85 years
Trial Updated:
04/23/2024
Locations: Integrative Cardiovascular Physiology Laboratory, University of Florida, Gainesville, Florida
Conditions: Breast Cancer
Register for Updates
[18F] F-GLN by PET/CT in Breast Cancer
NCT03863457
Recruiting
Patients with known or suspected primary or metastatic breast cancer with one lesion that is 1.5 cm in diameter or greater may be eligible for this study. Patients may participate in this study if they are at least 18 years of age. Up to 40 evaluable subjects will participate in a single imaging cohort. Patients will be stratified for analysis by breast cancer subtype with prioritization to recruit at least 10 estrogen-receptor-expressing (ER+) and 10 triple-negative breast cancers (TNBC). This... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Breast Cancer
Register for Updates
Biomarkers to Detect Endocrine Therapy Resistance
NCT06067503
Recruiting
This pilot observational study is being done to identify possible biomarkers of response to endocrine therapy in patients with ER/PR+ metastatic lobular breast cancer (LBC) starting new endocrine therapy. 18F-fluorofuranylnorprogesterone Positron Emission Tomography/Computed Tomography (FFNP-PET/CT) and liquid biopsies will be performed at baseline and after 4 weeks of treatment. Baseline levels and dynamic on-treatment changes in estrogen signaling as measured by FFNP-PET/CT and circulating tum... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: UW Carbone Cancer Center, Madison, Wisconsin
Conditions: Metastatic Cancer, Breast Cancer, Lobular Breast Carcinoma
Register for Updates
A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
NCT05989724
Recruiting
This proposed Phase I clinical trial of SON-DP is an FIH, open-label, Phase Ia/Ib dose escalation and expansion study to evaluate the safety, tolerability, PK, and PD of SON-DP in participants with relapsed/refractory/intolerant to standard of care therapies, for advanced/ metastatic solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Banner MD Anderson Cancer Center (BMDACC), Gilbert, Arizona +4 locations
Conditions: Solid Tumor, Breast Cancer, Pancreatic Cancer, Ovarian Cancer, Colorectal Cancer
Register for Updates